Would you like to join us as an event supporter? Email firstname.lastname@example.org for all the details.
VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania , is a global independent provider of product and service solutions to laboratory and production customers. With sales in excess of $4.5 billion in 2016, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries. With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers' productivity from research to production. VWR's differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of more than 10,200 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.
For more information or an introduction, please email us.
Helping shape a new age of healthcare
There is no other life sciences company quite like GE Healthcare’s Life Sciences business. Part of GE Healthcare, we are a $4 billion business of 11,500 people in over 100 countries, at work enabling a new era in medicine. We have the agility and unmatched global capabilities that come with being part of a company that continually pushes the frontiers of science and technology.
For more than 60 years, GE Healthcare Life Sciences has supported the development and use of new therapies, helping accelerate the journey from biological understanding to clinical therapy. At GE Healthcare Life Sciences, we believe that the practice of science and medicine is at a turning point; we are on the cusp of understanding biological and genetic mysteries and uncovering treatments for complex diseases that would have been unthinkable just a few years ago. We are supporting the development of more personalized and targeted therapies by advancing cell therapy. We are helping healthcare practitioners gain new understanding of the body and enabling earlier and more precise diagnosis of disease with our imaging technologies. And as the development of molecules and medicines becomes more complex, we are reimagining the processes and manufacturing operations that make large scale biopharmaceutical production possible.
Headquartered in the United Kingdom, we provide expertise and tools in biotechnology, life sciences and clinical diagnostics, supporting fields from basic cell, protein and drug discovery research, to large-scale biopharmaceutical manufacturing, and diagnostic imaging in diseases such as cancer, heart disease and neurological disorders.
For more information about GE Healthcare, visit www.gehealthcare.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.
Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.
For more information on Horizon Discovery, visit www.horizondiscovery.com
Risk management solutions for life sciences companies are often complex and specialist. By choosing the Gallagher Life Sciences Practice, you will work with an insurance broker with thorough knowledge of your industry and the regulatory environment. The Life Sciences Practice will leverage the marketplace on your behalf to help protect your company’s bottom line from the financial devastation that could result from a loss or lawsuit. Our team of specialists will work with you to customise risk management and insurance solution programs that meet your unique needs and protect your organisation.
Our Gallagher life sciences team has experience in nearly every phase of the life science process - from discovery to development to production. This includes insuring human clinical trials in most countries around the world. Whether you’re a start-up or a multinational, whether you’re operating in the UK or overseas, we help to prepare a range of bespoke insurance solutions that may include:
- Clinical Trials Liability
- Products Liability and Product Recall
- Property coverage at your premises, at third party locations or in Transit
- Business Interruption cover for loss of income or unproductive cash burn
- Directors’ and Officers’ Liability
- Intellectual Property Infringement Defence and/or Pursuit
- Errors and Omissions and Professional L:iability
- Medical Malpractice
- Cyber Risks
For more information or an introduction, please email us.
BioIndustry Association is an introducer appointed representative of Arthur J. Gallagher Insurance Brokers Limited which is authorised and regulated by the Financial Conduct Authority. Registered Office: Spectrum Building 7th Floor, 55 Blysthwood Street, Glasgow, G2 7AT. Registered in Scotland. Company Number: SC108909.
Terms and conditions of the promotion:
LifeArc® is a medical research charity that pioneers new ways to turn great science into greater patient impact. We have a 25 year legacy of helping scientists and organisations
advance their research into therapeutics and diagnostics for patients, including Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’s disease) and a test for antimicrobial resistance. Find out more about how we fund, protect and develop much needed research at lifearc.org or Twitter @lifearc1
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation – JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
MedImmune is the worldwide biologics research and development arm of AstraZeneca with its headquarters in Gaithersburg, Maryland (US).
MedImmune has a robust pipeline of over 120 biologic medicines in R&D, with more than 30 in clinical stage development. The company’s marketed products include Synagis® (palivizumab) and Fluenz® (live attenuated influenza vaccine, LAIV).
MedImmune has built on the local legacy of Cambridge Antibody Technology, leaders in antibody technology who discovered three marketed medicines: Humira® (adalimumab), an important anti-TNF antibody now marketed by Abbott Laboratories.1 , Benlysta® (belimumab), a first new treatment for active systemic lupus erythematosus in decades, now marketed by Human Genome Sciences and GlaxoSmithKline2 and ABthrax® (raxibacumab) anti-anthrax antibody marketed by Human Genome Sciences and GlaxoSmithKline.
Committed to Cambridge, and firmly established in local business networks and community activities, MedImmune is proud of its strong and enduring collaborative links with academics, researchers, charities, foundations and neighbouring companies. Employing approximately 500 people, the MedImmune Cambridge site is a major R&D hub supporting the research and early development of the biologics portfolio, contributing to all of the MedImmune therapy areas.
By 2016, MedImmune will be joined in Cambridge by AstraZeneca’s new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedical Campus, bringing together AstraZeneca’s small molecule and MedImmune’s biologics research and development.
(1 Humira is a registered trademark of AbbVie Inc.; 2 Benlysta is a registered trademark of GlaxoSmithKline)